Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

-- SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients --

-- Conference Call Wednesday, Jan. 20, 2016, at 8:30 a.m. (ET); Mark Pimentel, MD, FRCP(C) Featured Guest Speaker --

Jan 19, 2016, 16:32 ET from Synthetic Biologics, Inc.